Woodline Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Woodline Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.37M	Buy	155,302 +5,000	+3%	+$278K	0.03%	550
2026 Q1	$8.74M	Buy	+150,302	New	+$6.93M	0.03%	547
2025 Q3	–	Sell	-43,380	Closed	-$1.36M	–	1068
2025 Q2	$1.36M	Buy	+43,380	New	+$1.42M	0.01%	774
2025 Q1	–	Sell	-39,938	Closed	-$1.57M	–	1053
2024 Q4	$1.57M	Buy	+39,938	New	+$1.65M	0.01%	693
2024 Q1	–	Sell	-196,453	Closed	-$9.05M	–	649
2023 Q4	$9.05M	Buy	196,453 +53,002	+37%	+$1.87M	0.1%	242
2023 Q3	$4.9M	Sell	143,451 -146,949	-51%	-$5.5M	0.06%	312
2023 Q2	$11.2M	Sell	290,400 -129,629	-31%	-$5.15M	0.13%	194
2023 Q1	$15M	Buy	420,029 +121,589	+41%	+$4.49M	0.2%	141
2022 Q4	$11.8M	Sell	298,440 -105,919	-26%	-$3.86M	0.16%	182
2022 Q3	$14.6M	Buy	404,359 +175,431	+77%	+$6.31M	0.2%	147
2022 Q2	$6.96M	Buy	+228,928	New	+$6.92M	0.11%	216
2021 Q4	–	Sell	-199,984	Closed	-$3.06M	–	797
2021 Q3	$3.06M	Buy	+199,984	New	+$3.48M	0.05%	334

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Woodline Partners's XENE Position: Q2 2026 in Review

Woodline Partners increased its Xenon Pharmaceuticals (XENE) stake by 3.3% in Q2 2026, buying an estimated $278K and bringing the position to 155,302 shares worth $9.37M. The position accounts for 0.03% of the portfolio, ranked #550.

Woodline Partners first reported a position in XENE in Q3 2021 and has held it in 12 quarters since. The position peaked at $15M in Q1 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Woodline Partners held 155,302 shares of Xenon Pharmaceuticals worth $9.37M as of Q2 2026.
Woodline Partners bought 5,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $278K.
Xenon Pharmaceuticals made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #550 holding.
Woodline Partners first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
Woodline Partners's Xenon Pharmaceuticals position peaked at $15M in Q1 2023.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.